Study end points
The prespecified primary end point was the change in HIV-1 reactivation at treatment initiation and at the end of treatment in the study arms, measured as the change in CA US HIV-1 RNA between treatment initiation (day 0 at 0 hours) and at the end of the study (day 42). Secondary end points reported here included the change in inducible HIV-1 reservoir size as quantified by TILDA, the synergistic effects of pyrimethamine with VPA on the induction of CA US HIV-1 RNA, the change in CA US HIV-1 RNA between time points within and between study arms, plasma HIV-1 RNA changes, the pharmacokinetic and pharmacodynamic profiles of the intervention regimens, and the clinical safety and tolerability of the intervention regimen.